Individuals with scores in the fourth quartile (scores 7–10) are four times more likely to be admitted to hospital than those with scores in the first quartile (0 – 2) ( Ong et al 2005). The BODE is also strongly associated with patient-centred outcomes. Individuals with scores

in the fourth quartile are four times more likely to have depressive symptoms than those in quartiles one and two ( Al-shair et al 2009). Responsiveness: The BODE index detects clinical deterioration and changes occurring as a result of therapy. Scores increase during an acute exacerbation of COPD as a result of worsening FEV1, dyspnoea and 6MWD ( Cote 2007). Lung volume reduction surgery improves the BODE index in patients with severe COPD as a result of changes see more in FEV1 and dyspnoea score ( Lederer et al 2007). Pulmonary rehabilitation improves average BODE score by 0.9 points in patients with moderate to severe COPD ( Cote et al 2005), reflecting the well-established effects of this treatment on 6MWD and dyspnoea. Reliability, validity and discrimination:

The reliability and validity of the BODE index have Crizotinib purchase not been formally evaluated, however its four components have good clinimetric properties. The index was developed in a cohort recruited from three countries and demonstrated similar predictive qualities in all locations ( Celli et al 2004), suggesting it is broadly applicable to patients with COPD. The BODE index discriminates between high and low risk of death more accurately than FEV1 alone ( Celli et al 2004). Threshold for clinically important change: A one unit change in the BODE index has been suggested as Cediranib (AZD2171) clinically significant ( Cote et al 2005), based on thresholds for important change in individual

component scores. This was confirmed in a large sample of patients with severe airflow obstruction, where a one unit increase in BODE over six months was associated with increased mortality ( Martinez et al 2008). This study included highly selected patients participating in a trial of lung volume reduction surgery and it is unclear whether the threshold is equally applicable to a more general population of COPD patients. Chronic obstructive pulmonary disease has systemic manifestations that have an important influence on clinical outcome. The BODE index measures functional limitation, nutritional status and symptoms, in addition to airflow obstruction, and is therefore well placed to assess clinical risk and the integrated response to treatment. All components of the BODE index are routinely collected during a pulmonary rehabilitation assessment and calculation of the BODE score is quick and easy in this setting. However some components of the BODE, such as the 6MWD, may not be routinely available outside pulmonary rehabilitation programs.